Dr. John L. Kulp III is CEO at Conifer Point Pharmaceuticals, a company that leverages advanced computational tools to accelerate the discovery of small-molecule therapeutics. He has a Ph.D. in Chemistry from New York University. His Ph.D. work focused on stabilizing α-helical peptides for development as a new class of drug molecules and the study of peptide/protein structure by NMR. He subsequently worked on the development of novel inhibitors for multiple drug-targets including DHFR, PCSK9, 11β-HSD, and recA. John created Conifer Point in 2014, and he has worked with Evrys Bio on sirtuin proteins since 2015. He has served as PI on multiple NIH grants, and his work has produced numerous patents/patent applications and publications. John’s passion in promoting STEM careers resulted in his founding of a satellite campus for the Geisinger Commonwealth School of Medicine and, independently, an after-school program for high school students in Bucks County, PA.
Dr. John L. Kulp III is CEO at Conifer Point Pharmaceuticals, a company that leverages advanced computational tools to accelerate the discovery of small-molecule therapeutics. He has a Ph.D. in Chemistry from New York University. His Ph.D. work focused on stabilizing α-helical peptides for development as a new class of drug molecules and the study of peptide/protein structure by NMR. He subsequently worked on the development of novel inhibitors for multiple drug-targets including DHFR, PCSK9, 11β-HSD, and recA. John created Conifer Point in 2014, and he has worked with Evrys Bio on sirtuin proteins since 2015. He has served as PI on multiple NIH grants, and his work has produced numerous patents/patent applications and publications. John’s passion in promoting STEM careers resulted in his founding of a satellite campus for the Geisinger Commonwealth School of Medicine and, independently, an after-school program for high school students in Bucks County, PA.